COVID-19: breaking down a global health crisis.
COVID-19: breaking down a global health crisis.
复制标题
DOI：
10.1186/s12941-021-00438-7
复制
发表时间：
2021-05-18
影响因子：
5.7
通讯作者：
Al-Qahtani M
中科院分区：
文献类型：
--
作者：
Mallah SI;Ghorab OK;Al-Salmi S;Abdellatif OS;Tharmaratnam T;Iskandar MA;Sefen JAN;Sidhu P;Atallah B;El-Lababidi R;Al-Qahtani M
2019年冠状病毒病（COVID-19）是21世纪的第二次大流行，迄今已有1亿多人感染，200多万人死亡。它是冠状病毒科的一种新型毒株，被命名为严重急性呼吸窘迫综合征冠状病毒-2 (SARS-CoV-2)；这是继中东呼吸综合征（MERS）和严重急性呼吸窘迫综合征（SARS）之后，已知的第7个导致人类疾病的冠状病毒家族成员。这种单链RNA分子最显著的特征包括其表面的刺突糖蛋白。大多数COVID-19患者，其中老年人和免疫功能低下的风险最大，主诉有流感样症状，包括干咳和头痛。最常见的并发症包括肺炎、急性呼吸窘迫综合征、感染性休克和心血管症状。SARS-CoV-2主要通过呼吸道飞沫传播，感染患者咳嗽或打喷嚏时直接从空气中传播，或者以表面污染物的形式传播。保持手部卫生、保持社交距离和使用个人防护设备（即口罩）仍然是最有效的预防措施。患者管理包括支持性护理和抗凝措施，重点是维持呼吸功能。迄今为止，地塞米松、瑞德西韦和托珠单抗似乎是最有希望的治疗方法，羟氯喹、洛匹那韦、利托那韦和干扰素已不再受欢迎。此外，国际上加快了疫苗接种工作，正在大规模部署几种有希望的疫苗接种。为应对COVID-19大流行，各国和利益攸关方采取了各种预防措施，以对抗和遏制病毒的传播，并减轻其附带的经济损失。本文的目的是综合该病毒在全球、微观到宏观的影响。
Coronavirus disease 2019 (COVID-19) is the second pandemic of the twenty-first century, with over one-hundred million infections and over two million deaths to date. It is a novel strain from the Coronaviridae family, named Severe Acute Respiratory Distress Syndrome Coronavirus-2 (SARS-CoV-2); the 7th known member of the coronavirus family to cause disease in humans, notably following the Middle East Respiratory syndrome (MERS), and Severe Acute Respiratory Distress Syndrome (SARS). The most characteristic feature of this single-stranded RNA molecule includes the spike glycoprotein on its surface. Most patients with COVID-19, of which the elderly and immunocompromised are most at risk, complain of flu-like symptoms, including dry cough and headache. The most common complications include pneumonia, acute respiratory distress syndrome, septic shock, and cardiovascular manifestations. Transmission of SARS-CoV-2 is mainly via respiratory droplets, either directly from the air when an infected patient coughs or sneezes, or in the form of fomites on surfaces. Maintaining hand-hygiene, social distancing, and personal protective equipment (i.e., masks) remain the most effective precautions. Patient management includes supportive care and anticoagulative measures, with a focus on maintaining respiratory function. Therapy with dexamethasone, remdesivir, and tocilizumab appear to be most promising to date, with hydroxychloroquine, lopinavir, ritonavir, and interferons falling out of favour. Additionally, accelerated vaccination efforts have taken place internationally, with several promising vaccinations being mass deployed. In response to the COVID-19 pandemic, countries and stakeholders have taken varying precautions to combat and contain the spread of the virus and dampen its collateral economic damage. This review paper aims to synthesize the impact of the virus on a global, micro to macro scale.
登录
查看更多内容
影响因子：
158.5
作者：
Ackermann, Maximilian;Verleden, Stijn E.;Jonigk, Danny
通讯作者：
Jonigk, Danny
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.23750/abm.v91i1.9402
发表时间：
2020-03-19
期刊：
Acta bio-medica : Atenei Parmensis
影响因子：
--
作者：
Baglivo M;Baronio M;Natalini G;Beccari T;Chiurazzi P;Fulcheri E;Petralia PP;Michelini S;Fiorentini G;Miggiano GA;Morresi A;Tonini G;Bertelli M
通讯作者：
Bertelli M
影响因子：
2.5
作者：
Arabi, Yaseen M.;Asiri, Ayed Y.;Hussein, Mohamed A.
通讯作者：
Hussein, Mohamed A.
影响因子：
39
作者：
Abella BS;Jolkovsky EL;Biney BT;Uspal JE;Hyman MC;Frank I;Hensley SE;Gill S;Vogl DT;Maillard I;Babushok DV;Huang AC;Nasta SD;Walsh JC;Wiletyo EP;Gimotty PA;Milone MC;Amaravadi RK;Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators
通讯作者：
Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators